Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 2/20 | 0.57 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | ABL1 | P00519 | 1/20 | 0.56 |
| ▸ | ALPL | P05186 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | ALPG | P10696 | 1/20 | 0.56 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.56 |
| ▸ | RECQL | P46063 | 1/20 | 0.56 |
| ▸ | GALK1 | P51570 | 1/20 | 0.56 |
| ▸ | CASP7 | P55210 | 1/20 | 0.56 |
| ▸ | CASP6 | P55212 | 1/20 | 0.56 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.56 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.56 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.56 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.54 |
| ▸ | TYR | P14679 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8838916 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL18733414 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL19479665 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL7152381 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL5265603 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL8838912 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL5026363 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL2621553 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL5026358 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL | |
| SCHEMBL9849310 | 1.00 | SLC6A2 (0.57) | SLC6A2SYNJ2KDM4EABL1ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12023357-B2 | Rejuvenated aged hematopoietic stem cells and methods of use | HACKENSACK UNIVERSITY MEDICAL CENTER (US) | 2024-07-02 | — | — | US | disclosed |
| US-20220072098-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC | 2022-03-10 | — | — | US | disclosed |
| EP-3808177-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | Arbutus Biopharma Corporation (CA) | 2021-04-21 | — | — | EP | disclosed |
| US-10835612-B2 | Lipids and compositions for the delivery of therapeutics | ARBUTUS BIOPHARMA CORPORATION (CA) | 2020-11-17 | — | — | US | disclosed |
| EP-3238738-B1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORP (CA) | 2020-09-23 | — | — | EP | disclosed |
| US-20190231823-A1 | REJUVENATED AGED HEMATOPOIETIC STEM CELLS AND METHODS OF USE | HACKENSACK UNIVERSITY MEDICAL CENTER | 2019-08-01 | — | — | US | disclosed |
| US-20190216895-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | LAUREN SCIENCES LLC (US) | 2019-07-18 | — | — | US | disclosed |
| US-20180125985-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-05-10 | — | — | US | disclosed |
| US-20180064807-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | ARBUTUS BIOPHARMA CORPORATION (CA) | 2018-03-08 | — | — | US | disclosed |
| EP-3283060-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | Lauren Sciences LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-6462193-B1 | ADDING 3-AZIDO-2-HYDROXYPROPANALDEHYDE WITH DIHYDROXYACETONE PHOSPHATE USING AN ALDOLASE, HYDROLYZING THE INTERMEDIATE WITH ACID PHOSPHATASE, ISOMERIZING USING AN ISOMERASE, CYCLIZING USING REDUCTIVE AMINATION TO PRODUCE TETRAHYDROXYAZEPINE | THE SCRIPPS RESEARCH INSTITUTE | 2002-10-08 | — | — | US | disclosed |
| US-20010028977-A1 | Charging, discharging efficiency; vanadium electrolyte | JD HOLDING INC. (KY) | 2001-10-11 | — | — | US | disclosed |
| US-6294521-B1 | SUGAR PHOSPHATES | AUSTRALIAN NATIONAL UNIVERSITY (AU) | 2001-09-25 | — | — | US | disclosed |
| US-6143443-A | ALL-VANADIUM REDOX BATTERY, COMPRISING THE STABILIZED ELECTROLYTE | PINNACLE ARB LIMITED (AU) | 2000-11-07 | — | — | US | disclosed |
| WO-1998037218-A1 | HYDROXYAZEPANES AS INHIBITORS OF GLYCOSIDASE AND HIV PROTEASE | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-08-27 | — | — | WO | disclosed |
| EP-0829104-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1998-03-18 | — | — | EP | disclosed |
| EP-0729648-A4 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LTD (AU) | 1997-01-02 | — | — | EP | disclosed |
| WO-1996035239-A1 | HIGH ENERGY DENSITY VANADIUM ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND ALL-VANADIUM REDOX CELLS AND BATTERIES CONTAINING HIGH ENERGY VANADIUM ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-11-07 | — | — | WO | disclosed |
| EP-0729648-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1996-09-04 | — | — | EP | disclosed |
| WO-1995012219-A1 | STABILISED ELECTROLYTE SOLUTIONS, METHODS OF PREPARATION THEREOF AND REDOX CELLS AND BATTERIES CONTAINING STABILISED ELECTROLYTE SOLUTIONS | UNISEARCH LIMITED (AU) | 1995-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180125985-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | SLC6A2 2280/4885SYNJ2 602/4885KDM4E 3941/4885 |
| US-20190216895-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | GFRA2, GFRA1, NGF | SLC6A2 239/4885SYNJ2 3466/4885KDM4E 4648/4885 |
| US-20220072098-A1 | BOLAAMPHIPHILIC COMPOUNDS, COMPOSITIONS AND USES THEREOF | GFRA2, GFRA1, NGF | SLC6A2 269/4885SYNJ2 3438/4885KDM4E 4638/4885 |
| US-20180064807-A1 | NOVEL LIPIDS AND COMPOSITIONS FOR THE DELIVERY OF THERAPEUTICS | CETP, LCAT, NPC1L1 | SLC6A2 2307/4885SYNJ2 609/4885KDM4E 3900/4885 |
| US-10835612-B2 | Lipids and compositions for the delivery of therapeutics | CETP, LCAT, LIPA | SLC6A2 1701/4885SYNJ2 710/4885KDM4E 3778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.